Company / Net Income
Spyre Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$155.2M
FY2025
5-year range
-$338.8M / -$65.8M
FY2021-FY2025
Trend
+25.4%
vs FY2024
Sector context
#135 of 216
Health Care
What the data says
At -$155M, Spyre Therapeutics, Inc.'s net income ranks #135 of 216 in the Health Care sector. Net Income has fluctuated over the past 10 years, ranging from -$339M in FY2023 to -$22M in FY2018.
Based on SEC 10-K filings.
-$155M in FY2025.
Improved from -$339M to -$155M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#135 of 216 in Health CareTop 62% of 216This company -$155.2M Sector average $454.3M
▼
-134.2% below sector average
Key checks
Key Insights
- In FY2025, net income increased 25.4% year-over-year.
- Ranks #135 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$155.2M | +25.4% |
| FY2024 | -$208.0M | +38.6% |
| FY2023 | -$338.8M | -318.8% |
| FY2022 | -$80.9M | -22.9% |
| FY2021 | -$65.8M | -48.4% |
| FY2020 | -$44.3M | -62.8% |
| FY2019 | -$27.2M | -25.5% |
| FY2018 | -$21.7M | +20.3% |
| FY2017 | -$27.2M | -25.5% |
| FY2016 | -$21.7M | -92.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026